The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
Open accessAbstract
Purpose: The objective is to investigate whether polymorphisms with putative influence on fluorouracil/oxaliplatin activity are associated with clinical outcomes of patients with advanced colorectal cancer treated with first-line oxaliplatin, folinic acid, and fluorouracil palliative chemotherapy. Materials and Methods: Consecutive patients were prospectively enrolled onto medical oncology units in Central Italy. Patients were required to have cytologically/histologically confirmed metastatic disease with at least one measurable lesion. Peripheral blood samples were used for genotyping 12 polymorphisms in thymidylate synthase, methylenetetrahydrofolate reductase, xeroderma pigmentosum group D (XPD), excision repair cross complementing group 1 (ERCC1), x-ray cross complementing group 1, x-ray cross complementing protein 3, glutathione S-transferases (GSTs) genes. The primary end point of the study was to investigate the association between genotypes and progression-free survival (PFS). Results: In 166 patients, ERCC1-118 T/T, XPD-751 A/C, and XPD-751 C/C genotypes were independently associated with adverse PFS. The presence of two risk genotypes (ERCC1-118 T/T combined with either XPD-751 A/C or XPD-751 C/C) occurred in 50 patients (31%). This profiling showed an independent role for unfavorable PFS with a hazard ratio of 2.84% and 95% CI of 1.47 to 5.45 (P = .002). Neurotoxicity was significantly associated with GSTP1-105 A/G. Carriers of the GSTP1-105 G/G genotype were more prone to suffer from grade 3 neurotoxicity than carriers of GSTP1-105 A/G and GSTP1-105 A/A genotypes. Conclusion: A pharmacogenetic approach may be an innovative strategy for optimizing palliative chemotherapy in patients with advanced colorectal cancer. These findings deserve confirmation in additional prospective studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,092
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Watson, M. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.275 · Cited by 668
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V, Xiong, Y.-P., Ingles, S. A., Sherrod, A., Warren, R., Tsao-Wei, D., Groshen, S., & Lenz, H.-J. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500012 · Cited by 571
Horie, N., Aiba, H., Oguro, K., Hojo, H., & Takeishi, K. (1995) · Cell Structure and Function · doi:10.1247/csf.20.191 · Cited by 547
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.
Spitz, M. R., Wu, X., Wang, Y., Wang, L.-E., Shete, S. S., Amos, C. I., Guo, Z., Lei, L., Mohrenweiser, H. W., & Wei, Q. (2001) · PubMed · Cited by 489
Popat, S., Matakidou, A., & Houlston, R. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.064 · Cited by 449
XPD polymorphisms: effects on DNA repair proficiency
Lunn, R. M., Helzlsouer, K. J., Parshad, R., Umbach, D. M., Harris, E. L., Sanford, K. K., & Bell, D. A. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.551 · Cited by 431
Choudhuri, S., & Klaassen, C. D. (2006) · International Journal of Toxicology · doi:10.1080/10915810600746023 · Cited by 415
Arnaudeau, C., Lundin, C., & Helleday, T. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4564 · Cited by 386
Stoehlmacher, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.936 · Cited by 384
Stoehlmacher, J., Park, D. J., Zhang, W., Yang, D., Groshen, S., Zahedy, S., & Lenz, H.-J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601975 · Cited by 364
Mandola, M. V., Stoehlmacher, J., Muller‐Weeks, S., Cesarone, G., Yu, M. C., Lenz, H., & Ladner, R. D. (2003) · PubMed · Cited by 362
Furuta, T., Ueda, T., Aune, G. J., Sarasin, A. R., Kraemer, K. H., & Pommier, Y. G. (2002) · PubMed · Cited by 349
Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L. M., Pessa, S., Errante, D., De Pangher, V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5400 · Cited by 338
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Sobrero, A. F., Aschele, C., & Bertino, J. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.368 · Cited by 336
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Kelly, H., & Goldberg, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.749 · Cited by 316
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., & Baiget, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602042 · Cited by 315
A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies
Abdel-Rahman, S. Z., El-Zein, R. A., Anwar, W. A., & Au, W. W. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04832-x · Cited by 298
Mandola, M. V., Stoehlmacher, J., Zhang, W., Groshen, S., Yu, M. C., Iqbal, S., Lenz, H.-J., & Ladner, R. D. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00007 · Cited by 298
Kawakami, K., Omura, K., Kanehira, E., & Watanabe, Y. (1999) · PubMed · Cited by 282
Carlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., Rogatko, A., Wang, H., & Blanchard, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1226.11.3 · Cited by 262
Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays.
Au, W. W., Salama, S. A., & Sierra-Torres, C. H. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6632 · Cited by 260
Ulrich, C. M., Bigler, J., Velicer, C. M., Greene, E. A., Farin, F. M., & Potter, J. D. (2000) · PubMed · Cited by 259
Paz, M. F., Avila, S., Fraga, M. F., Pollán, M., Capellá, G., Peinado, M. A., Sánchez‐Céspedes, M., Herman, J. G., & Esteller, M. (2002) · PubMed · Cited by 244
Kawakami, K., & Watanabe, G. (2003) · PubMed · Cited by 240
Sohn, K.-J., Croxford, R., Yates, Z., Lucock, M., & Kim, Y.-I. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh015 · Cited by 221
Lecomte, T., Landi, B., Beaune, P., Laurent-Puig, P., & Loriot, M.-A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2076 · Cited by 211
Jakobsen, A., Nielsen, J. N., Gyldenkerne, N., & Lindeberg, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.219 · Cited by 191
Goto, S., Iida, T., Cho, S., Oka, M., Kohno, S., & Kondo, T. (1999) · Free Radical Research · doi:10.1080/10715769900301121 · Cited by 187
Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., & Rozen, R. R. (2003) · PubMed · Cited by 183
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
KWEEKEL, D., GELDERBLOM, H., & GUCHELAAR, H. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.12.006 · Cited by 179
XRCC3 is required for efficient repair of chromosome breaks by homologous recombination
Brenneman, M. A., Weiss, A. E., Nickoloff, J. A., & Chen, D. J. (2000) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(00)00002-1 · Cited by 177
Weaver, D. A., Crawford, E. L., Warner, K. A., Elkhairi, F., Khuder, S., & Willey, J. C. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-18 · Cited by 171
Falcone, A., Masi, G., Allegrini, G., Danesi, R., Pfanner, E., Brunetti, I. M., Paolo, A. D., Cupini, S., Tacca, M. D., & Conte, P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.075 · Cited by 164
Self-citationNegri, F., Wotherspoon, A. C., Cunningham, D., Norman, A. R., Chong, G., & Ross, P. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi244 · Cited by 161
Étienne-Grimaldi, M.-C., Formento, J., Chazal, M., Francoual, M., Magn�, N., Formento, P., Bourgeon, A., Seitz, J.-F., Delpéro, J., Létoublon, C., et al. (2004) · Pharmacogenetics · doi:10.1097/00008571-200412000-00001 · Cited by 134
Marcuello, E., Altés, A., del Río, E., César, A., Menoyo, A., & Baiget, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20487 · Cited by 125
Dotor, E., Cuatrecases, M., Martínez‐Iniesta, M., Navarro, M., Vilardell, F., Guinó, E., Pareja, L., Figueras, A., Mollevı́, D. G., Serrano, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.5253 · Cited by 125
Seker, H., Butkiewicz, D., Bowman, E. D., Rusin, M., Hedayati, M. A., Grossman, L. I., & Harris, C. C. (2001) · PubMed · Cited by 125
Nagar, S., & Blanchard, R. L. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600739835 · Cited by 114
Identifying Functional Genetic Variants in DNA Repair Pathway Using Protein Conservation Analysis
Savas, S., Kim, D. Y., Ahmad, M., Shariff, M., & Özçelik, H. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.801.13.5 · Cited by 114
Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks
Araujo, F. D., Pierce, A. J., Stark, J. M., & Jasin, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205539 · Cited by 109
Etienne, M. C., Ilc, K., Formento, J. L., Laurent‐Puig, P., Formento, P., Chéradame, S., Fischel, J.-L., & Milano, G. A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601523 · Cited by 106
Louvet, C., de Gramont, A., Tournigand, C., Artru, P., Maindrault-Goebel, F., & KRULIK, M. (2001) · Cancer · doi:10.1002/1097-0142(20010601)91:11<2033::aid-cncr1229>3.0.co;2-j · Cited by 83
Polymorphisms in DNA repair and environmental interactions
de Boer, J. G. (2002) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(02)00217-8 · Cited by 81
Marcuello, E., Altés, A., Menoyo, A., del Rı́o, E., & Baiget, M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0089-1 · Cited by 79
Xu, Z.-Y., Loignon, M., Han, F.-Y., Panasci, L., & Aloyz, R. S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084053 · Cited by 69
Molecular determinants of irinotecan efficacy
Vallböhmer, D., Iqbal, S., Yang, D., Rhodes, K. E., Zhang, W., Gordon, M. A., Fazzone, W., Schultheis, A. M., Sherrod, A. E., Danenberg, K. D., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22129 · Cited by 65
Kealey, C., Brown, K. S., Woodside, J. V., Young, I. S., Murray, L., Boreham, C. A., McNulty, H., Strain, J., McPartlin, J. M., Scott, J. M., et al. (2005) · Human Genetics · doi:10.1007/s00439-004-1243-2 · Cited by 58
Pullmann, R., Abdelmohsen, K., Lal, A., Martindale, J. L., Ladner, R. D., & Gorospe, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600282200 · Cited by 55
Wu, J., Yin, M.-B., Hapke, G., Tóth, K., & Rustum, Y. M. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12324-3 · Cited by 53
A clinical nomogram for predicting long-term survival in advanced colorectal cancer
Massacesi, C., Norman, A. R., Price, T. J., Hill, M. E., Ross, P. J., & Cunningham, D. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00286-0 · Cited by 52
Massacesi, C., Pistilli, B., Valeri, M., Lippe, P., Rocchi, M., Cellerino, R., & Piga, A. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200204000-00008 · Cited by 26
Cited by
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0636 · Cited by 335
Kap, E. J., Seibold, P., Richter, S., Scherer, D., Habermann, N., Balavarca, Y., Jansen, L., Becker, N., Pfütze, K., Popanda, O., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.8 · Cited by 20
Metadata
- Authors
- Ruzzo, A., Graziano, F., Loupakis, F., Rulli, E., Canestrari, E., Santini, D., Catalano, V., Ficarelli, R., Maltese, P., Bisonni, R., Masi, G., Schiavon, G., Giordani, P., Giustini, L., Falcone, A., Tonini, G., Silva, R., Mattioli, R., Floriani, I., & Magnani, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-04-01
- Volume
- 25
- Issue
- 10
- Pages
- 1247-1254
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139687160
- Cited by
- 266
- References
- 64
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.